The ability of GLP-1 RAs to do everything largely stems from the activation of GLP-1 receptors across numerous organs and tissues in the body, well beyond the pancreas
The demonstrated activity of orally administered BPC-157 in gastrointestinal models confirms sufficient stability in gastric juice and resistance to complete enzymatic degradation during intestinal transit, at least for local mucosal effects if not systemic absorption
Clinical studies, including the STEP 1 extension trial with semaglutide 2.4 mg, have shown that patients often regain a significant proportion of weight lost during GLP-1 therapy, typically over several months
However, GLP-1(2836) did not affect mitochondrial glucose oxidation in caSMCs cultured in high-glucose medium (Supplemental Figure 12A)
Overall, a recent meta-analysis that reviewed the evidence of cannabis and CBD on UC and CD was unable to make any firm conclusions on their safety or efficacy in IBD [177,178]